BFA
RNAC icon

BlackRock Fund Advisors’s Cartesian Therapeutics RNAC Stock Holding History

BlackRock Fund Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$2.74M Buy
5,319
+767
+17% +$448K ﹤0.01% 3101
2016
Q3 		$1.95M Buy
+4,552
New +$1.78M ﹤0.01% 3167

Other funds holding RNAC

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock Fund Advisors's RNAC Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Cartesian Therapeutics (RNAC) stake by 17% in Q4 2016, buying an estimated $448K and bringing the position to 5,319 shares worth $2.74M. The position accounts for ﹤0.01% of the portfolio, ranked #3101.

BlackRock Fund Advisors first reported a position in RNAC in Q3 2016 and has held it in 2 quarters since. 43 funds tracked by Wall St. Rank hold RNAC as of Q4 2016.

  • BlackRock Fund Advisors held 5,319 shares of Cartesian Therapeutics worth $2.74M as of Q4 2016.
  • BlackRock Fund Advisors bought 767 Cartesian Therapeutics shares in Q4 2016, an estimated $448K.
  • Cartesian Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3101 holding.
  • BlackRock Fund Advisors first reported a position in Cartesian Therapeutics in Q3 2016 and has held it in 2 quarters since.
  • 43 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.